{"entity":{"edinet_code":"E00931","sec_code":"4516","name_ja":"日本新薬株式会社","name_en":"Nippon Shinyaku Co., Ltd.","industry":"医薬品","industry_en":"Pharmaceutical"},"names_note":"English company names are as filed: each company's own annual report states its English name on the cover page. For a company that files no annual report, EDINET's filer registry is used instead. The as-filed Japanese name is always returned alongside.","filing":{"doc_id":"S100YGRG","filer_name":"日本新薬株式会社","filer_name_en":"Nippon Shinyaku Co., Ltd.","period_end":"2026-03-31","filed_date":"2026-06-23","sha256":"5ca585bb8c67efd4186967248debf9de484003356510a24d1aebc6a555c65b56","status":"clean"},"basis":{"measurement":"carrying_amount","entity_scope":"parent_only","share_scope":"both","trust_included":"unknown","as_of":"2026-03-31","period_type":"annual","labels":{"measurement":"Balance-sheet carrying amount. Under Japanese GAAP listed equities are carried at market with the valuation difference in other comprehensive income, so carrying amount and acquisition cost diverge enormously on positions bought decades ago.","entity_scope":"The reporting company itself (提出会社) — the holding company, excluding the group holders it names separately.","share_scope":"Listed and unlisted shares together.","trust_included":"The filing does not state whether retirement-benefit-trust shares are included. Never guessed — shares contributed to such a trust leave the holder's balance sheet while the settlor normally keeps the right to instruct the vote.","period_type":"From an annual securities report (有価証券報告書). The policy shareholding table appears only in the annual report."},"not_comparable":"Figures are balance-sheet CARRYING AMOUNT at fiscal year end, from the annual securities report. They are NOT comparable with the acquisition-cost or book-value-reduction figures quoted in press coverage and IR presentations, and NOT comparable with interim (half-year) figures, which this product does not hold. Always state the basis with the number, and use check_claim before setting one of our figures against a published one."},"basis_note":"The basis every yen figure on this response is on. entity_scope is read from the filing's own disclosing entities, not assumed: scale_entities and flows each carry their own entity_scope and share_scope, and a figure quoted for one entity is not the group figure.","holdings":[{"holder_table":"reporting","held_name_raw":"Capricor Therapeutics Inc.","held_name_en":null,"held_sec_code":null,"match_status":"foreign","shares":4944429,"book_value_yen":24031000000,"prior_shares":4944429,"prior_book_value_yen":7015000000,"purpose_ja":"医薬品事業における関係の維持・強化を目的として保有しています。定量的な保有効果を示す事が困難なことから記載は省略していますが、「保有目的の合理性」と保有資産としての「経済的合理性」を検証し、2026年4月の取締役会において検証結果を確認、保有の可否を判断しています。","reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":null,"pct_share_classes":null,"pct_of_holder_equity":8.24246872759826,"pct_of_holder_assets":6.938176862734908,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":291551000000,"holder_total_assets_yen":346359000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"㈱三菱ＵＦＪフィナンシャル・グループ","held_name_en":"Mitsubishi UFJ Financial Group, Inc.","held_sec_code":"8306","match_status":"matched","shares":3324930,"book_value_yen":8644000000,"prior_shares":4824930,"prior_book_value_yen":9702000000,"purpose_ja":"金融取引関係の維持・強化を目的に株式を保有しています。定量的な保有効果を示す事が困難なことから記載は省略していますが、「保有目的の合理性」と保有資産としての「経済的合理性」を検証し、当事業年度（2025年度）に1,500,000株を売却しました。残りの株式については、2026年4月の取締役会において検証結果を確認、保有の可否を判断しています。","reciprocal":"有","pct_outstanding":0.029433671004224133,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":2.9648329108800864,"pct_of_holder_assets":2.495676451312078,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":291551000000,"holder_total_assets_yen":346359000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"㈱京都フィナンシャルグループ","held_name_en":"Kyoto Financial Group, Inc.","held_sec_code":"5844","match_status":"matched","shares":1599208,"book_value_yen":6494000000,"prior_shares":1599208,"prior_book_value_yen":3638000000,"purpose_ja":"金融取引関係の維持・強化を目的に株式を保有しています。定量的な保有効果を示す事が困難なことから記載は省略していますが、「保有目的の合理性」と保有資産としての「経済的合理性」を検証し、2026年4月の取締役会において検証結果を確認、保有の可否を判断しています。","reciprocal":"有","pct_outstanding":0.5629831581994615,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":2.227397607965673,"pct_of_holder_assets":1.8749332340144185,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":291551000000,"holder_total_assets_yen":346359000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"小野薬品工業㈱","held_name_en":"ONO　PHARMACEUTICAL　CO.,　LTD.","held_sec_code":"4528","match_status":"matched","shares":941000,"book_value_yen":2362000000,"prior_shares":941000,"prior_book_value_yen":1507000000,"purpose_ja":"協力関係の構築を目的に株式を保有しています。定量的な保有効果を示す事が困難なことから記載は省略していますが、「保有目的の合理性」と保有資産としての「経済的合理性」を検証し、2026年4月の取締役会において検証結果を確認、保有の可否を判断しています。","reciprocal":"有","pct_outstanding":0.19673610412754855,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.8101498537134155,"pct_of_holder_assets":0.6819513857009635,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":291551000000,"holder_total_assets_yen":346359000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"㈱メディパルホールディングス","held_name_en":"MEDIPAL HOLDINGS CORPORATION","held_sec_code":"7459","match_status":"matched","shares":791710,"book_value_yen":2326000000,"prior_shares":791710,"prior_book_value_yen":1848000000,"purpose_ja":"医薬品事業の販売取引関係の維持・強化を目的に株式を保有しています。定量的な保有効果を示す事が困難なことから記載は省略していますが、「保有目的の合理性」と保有資産としての「経済的合理性」を検証し、2026年4月の取締役会において検証結果を確認、保有の可否を判断しています。","reciprocal":"有","pct_outstanding":0.3867685648837866,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.797802099804151,"pct_of_holder_assets":0.6715575457834212,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":291551000000,"holder_total_assets_yen":346359000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"東京海上ホールディングス㈱","held_name_en":"Tokio Marine Holdings, Inc.","held_sec_code":"8766","match_status":"matched","shares":267340,"book_value_yen":1953000000,"prior_shares":300740,"prior_book_value_yen":1725000000,"purpose_ja":"損害保険取引関係の維持・強化を目的に株式を保有しています。定量的な保有効果を示す事が困難なことから記載は省略していますが、「保有目的の合理性」と保有資産としての「経済的合理性」を検証し、当事業年度（2025年度）に33,400株を売却しました。残りの株式については、2026年4月の取締役会において検証結果を確認、保有の可否を判断しています。","reciprocal":"有","pct_outstanding":0.014219740791582237,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.669865649577604,"pct_of_holder_assets":0.5638658155266645,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":291551000000,"holder_total_assets_yen":346359000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"㈱堀場製作所","held_name_en":"HORIBA, Ltd.","held_sec_code":"6856","match_status":"matched","shares":100000,"book_value_yen":1786000000,"prior_shares":100000,"prior_book_value_yen":994000000,"purpose_ja":"仕入取引関係の維持・強化を目的に株式を保有しています。定量的な保有効果を示す事が困難なことから記載は省略していますが、「保有目的の合理性」と保有資産としての「経済的合理性」を検証し、2026年4月の取締役会において検証結果を確認、保有の可否を判断しています。","reciprocal":"有","pct_outstanding":0.23811818815299152,"pct_unavailable":null,"pct_basis_period_end":"2025-12-31","pct_share_classes":1,"pct_of_holder_equity":0.6125857911651821,"pct_of_holder_assets":0.5156499470202882,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":291551000000,"holder_total_assets_yen":346359000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"三菱倉庫㈱","held_name_en":"Mitsubishi Logistics Corporation","held_sec_code":"9301","match_status":"matched","shares":1185000,"book_value_yen":1565000000,"prior_shares":1185000,"prior_book_value_yen":1145000000,"purpose_ja":"仕入取引関係の維持・強化を目的に株式を保有しています。定量的な保有効果を示す事が困難なことから記載は省略していますが、「保有目的の合理性」と保有資産としての「経済的合理性」を検証し、2026年4月の取締役会において検証結果を確認、保有の可否を判断しています。","reciprocal":"有","pct_outstanding":0.34558442766822417,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.5367843018888634,"pct_of_holder_assets":0.4518433186375986,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":291551000000,"holder_total_assets_yen":346359000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"東邦ホールディングス㈱","held_name_en":"TOHO HOLDINGS CO.,LTD.","held_sec_code":"8129","match_status":"matched","shares":325453,"book_value_yen":1549000000,"prior_shares":325453,"prior_book_value_yen":1451000000,"purpose_ja":"医薬品事業の販売取引関係の維持・強化を目的に株式を保有しています。定量的な保有効果を示す事が困難なことから記載は省略していますが、「保有目的の合理性」と保有資産としての「経済的合理性」を検証し、2026年4月の取締役会において検証結果を確認、保有の可否を判断しています。","reciprocal":"有","pct_outstanding":0.503179984700501,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.5312964112625236,"pct_of_holder_assets":0.44722383422980205,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":291551000000,"holder_total_assets_yen":346359000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"㈱島津製作所","held_name_en":"Shimadzu Corporation","held_sec_code":"7701","match_status":"matched","shares":206000,"book_value_yen":759000000,"prior_shares":206000,"prior_book_value_yen":768000000,"purpose_ja":"仕入取引関係の維持・強化を目的に株式を保有しています。定量的な保有効果を示す事が困難なことから記載は省略していますが、「保有目的の合理性」と保有資産としての「経済的合理性」を検証し、2026年4月の取締役会において検証結果を確認、保有の可否を判断しています。","reciprocal":"有","pct_outstanding":0.07127802576283343,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.2603318115869951,"pct_of_holder_assets":0.2191367915948481,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":291551000000,"holder_total_assets_yen":346359000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"キッセイ薬品工業㈱","held_name_en":"KISSEI PHARMACEUTICAL CO., LTD.","held_sec_code":"4547","match_status":"matched","shares":159700,"book_value_yen":742000000,"prior_shares":159700,"prior_book_value_yen":614000000,"purpose_ja":"医薬品製造の受託取引関係の維持・強化を目的に株式を保有しています。定量的な保有効果を示す事が困難なことから記載は省略していますが、「保有目的の合理性」と保有資産としての「経済的合理性」を検証し、2026年4月の取締役会において検証結果を確認、保有の可否を判断しています。","reciprocal":"有","pct_outstanding":0.3852640946770229,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.254500927796509,"pct_of_holder_assets":0.2142285894115643,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":291551000000,"holder_total_assets_yen":346359000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"科研製薬㈱","held_name_en":"KAKEN PHARMACEUTICAL CO., LTD.","held_sec_code":"4521","match_status":"matched","shares":171100,"book_value_yen":708000000,"prior_shares":171100,"prior_book_value_yen":766000000,"purpose_ja":"協力関係の構築を目的に株式を保有しています。定量的な保有効果を示す事が困難なことから記載は省略していますが、「保有目的の合理性」と保有資産としての「経済的合理性」を検証し、2026年4月の取締役会において検証結果を確認、保有の可否を判断しています。","reciprocal":"有","pct_outstanding":0.4494585088852772,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.2428391602155369,"pct_of_holder_assets":0.20441218504499667,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":291551000000,"holder_total_assets_yen":346359000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"㈱ジーエス・ユアサコーポレーション","held_name_en":"GS Yuasa Corporation","held_sec_code":"6674","match_status":"matched","shares":92400,"book_value_yen":487000000,"prior_shares":92400,"prior_book_value_yen":220000000,"purpose_ja":"仕入取引関係の維持・強化を目的に株式を保有しています。定量的な保有効果を示す事が困難なことから記載は省略していますが、「保有目的の合理性」と保有資産としての「経済的合理性」を検証し、2026年4月の取締役会において検証結果を確認、保有の可否を判断しています。","reciprocal":"有","pct_outstanding":0.09201900268091986,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.16703767093921817,"pct_of_holder_assets":0.14060555666230704,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":291551000000,"holder_total_assets_yen":346359000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"宝ホールディングス㈱","held_name_en":"TAKARA HOLDINGS INC.","held_sec_code":"2531","match_status":"matched","shares":300000,"book_value_yen":463000000,"prior_shares":300000,"prior_book_value_yen":343000000,"purpose_ja":"仕入取引関係の維持・強化を目的に株式を保有しています。定量的な保有効果を示す事が困難なことから記載は省略していますが、「保有目的の合理性」と保有資産としての「経済的合理性」を検証し、2026年4月の取締役会において検証結果を確認、保有の可否を判断しています。","reciprocal":"有","pct_outstanding":0.1555420866477991,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.15880583499970846,"pct_of_holder_assets":0.13367633005061222,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":291551000000,"holder_total_assets_yen":346359000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"㈱たけびし","held_name_en":"TAKEBISHI CORPORATION","held_sec_code":"7510","match_status":"matched","shares":154000,"book_value_yen":367000000,"prior_shares":154000,"prior_book_value_yen":279000000,"purpose_ja":"仕入取引関係の維持・強化を目的に株式を保有しています。定量的な保有効果を示す事が困難なことから記載は省略していますが、「保有目的の合理性」と保有資産としての「経済的合理性」を検証し、2026年4月の取締役会において検証結果を確認、保有の可否を判断しています。","reciprocal":"有","pct_outstanding":0.9608785175017158,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.12587849124166955,"pct_of_holder_assets":0.10595942360383302,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":291551000000,"holder_total_assets_yen":346359000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"日本ハム㈱","held_name_en":"NH Foods Ltd.","held_sec_code":"2282","match_status":"matched","shares":38500,"book_value_yen":270000000,"prior_shares":38500,"prior_book_value_yen":192000000,"purpose_ja":"機能食品事業の販売取引関係の維持・強化を目的に株式を保有しています。定量的な保有効果を示す事が困難なことから記載は省略していますが、「保有目的の合理性」と保有資産としての「経済的合理性」を検証し、2026年4月の取締役会において検証結果を確認、保有の可否を判断しています。","reciprocal":"無","pct_outstanding":0.04085656412808102,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.09260815431948441,"pct_of_holder_assets":0.07795379938156652,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":291551000000,"holder_total_assets_yen":346359000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"NISSHA㈱","held_name_en":"Nissha Co., Ltd.","held_sec_code":"7915","match_status":"matched","shares":124927,"book_value_yen":149000000,"prior_shares":124927,"prior_book_value_yen":170000000,"purpose_ja":"仕入取引関係の維持・強化を目的に株式を保有しています。定量的な保有効果を示す事が困難なことから記載は省略していますが、「保有目的の合理性」と保有資産としての「経済的合理性」を検証し、2026年4月の取締役会において検証結果を確認、保有の可否を判断しています。","reciprocal":"有","pct_outstanding":0.26018381793984785,"pct_unavailable":null,"pct_basis_period_end":"2025-12-31","pct_share_classes":1,"pct_of_holder_equity":0.051105981457789544,"pct_of_holder_assets":0.04301894854760523,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":291551000000,"holder_total_assets_yen":346359000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"北興化学工業㈱","held_name_en":"HOKKO CHEMICAL INDUSTRY CO.,LTD.","held_sec_code":"4992","match_status":"matched","shares":83490,"book_value_yen":142000000,"prior_shares":83490,"prior_book_value_yen":107000000,"purpose_ja":"協力関係の構築を目的に株式を保有しています。定量的な保有効果を示す事が困難なことから記載は省略していますが、「保有目的の合理性」と保有資産としての「経済的合理性」を検証し、2026年4月の取締役会において検証結果を確認、保有の可否を判断しています。","reciprocal":"有","pct_outstanding":0.3238515440317659,"pct_unavailable":null,"pct_basis_period_end":"2025-11-30","pct_share_classes":1,"pct_of_holder_equity":0.04870502930876588,"pct_of_holder_assets":0.04099792411919425,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":291551000000,"holder_total_assets_yen":346359000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"伊藤ハム米久ホールディングス㈱","held_name_en":"ITOHAM YONEKYU HOLDINGS INC.","held_sec_code":"2296","match_status":"matched","shares":23121,"book_value_yen":132000000,"prior_shares":23121,"prior_book_value_yen":96000000,"purpose_ja":"機能食品事業の販売取引関係の維持・強化を目的に株式を保有しています。定量的な保有効果を示す事が困難なことから記載は省略していますが、「保有目的の合理性」と保有資産としての「経済的合理性」を検証し、2026年4月の取締役会において検証結果を確認、保有の可否を判断しています。","reciprocal":"無","pct_outstanding":0.04074141157704892,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.04527509766730349,"pct_of_holder_assets":0.038110746364321414,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":291551000000,"holder_total_assets_yen":346359000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"㈱バイタルケーエスケー・ホールディングス","held_name_en":"VITAL KSK HOLDINGS,INC.","held_sec_code":"3151","match_status":"matched","shares":76734,"book_value_yen":112000000,"prior_shares":76734,"prior_book_value_yen":96000000,"purpose_ja":"医薬品事業の販売取引関係の維持・強化を目的に株式を保有しています。定量的な保有効果を示す事が困難なことから記載は省略していますが、「保有目的の合理性」と保有資産としての「経済的合理性」を検証し、2026年4月の取締役会において検証結果を確認、保有の可否を判断しています。","reciprocal":"有","pct_outstanding":0.15828924995393698,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.03841523438437872,"pct_of_holder_assets":0.03233639085457574,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":291551000000,"holder_total_assets_yen":346359000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"丸大食品㈱","held_name_en":"MARUDAI FOOD CO., LTD.","held_sec_code":"2288","match_status":"matched","shares":41604,"book_value_yen":94000000,"prior_shares":65504,"prior_book_value_yen":111000000,"purpose_ja":"機能食品事業の販売取引関係の維持・強化を目的に株式を保有しています。定量的な保有効果を示す事が困難なことから記載は省略していますが、「保有目的の合理性」と保有資産としての「経済的合理性」を検証し、当事業年度（2025年度）に23,900株を売却しました。残りの株式については、2026年4月の取締役会において検証結果を確認、保有の可否を判断しています。","reciprocal":"有","pct_outstanding":0.1704007813762972,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.032241357429746424,"pct_of_holder_assets":0.02713947089580464,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":291551000000,"holder_total_assets_yen":346359000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"滝沢ハム㈱","held_name_en":"TAKIZAWA HAM CO.,LTD.","held_sec_code":"2293","match_status":"matched","shares":15080,"book_value_yen":41000000,"prior_shares":14640,"prior_book_value_yen":41000000,"purpose_ja":"機能食品事業の販売取引関係の維持・強化を目的に株式を保有しています。定量的な保有効果を示す事が困難なことから記載は省略していますが、「保有目的の合理性」と保有資産としての「経済的合理性」を検証し、2026年4月の取締役会において検証結果を確認、保有の可否を判断しています。取引先持株会からの振替により株式数が増加しています。","reciprocal":"無","pct_outstanding":0.7343202181534866,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.01406271972999578,"pct_of_holder_assets":0.01183742879497862,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":291551000000,"holder_total_assets_yen":346359000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"㈱ほくやく・竹山ホールディングス","held_name_en":"HOKUYAKU TAKEYAMA Holdings,Inc.","held_sec_code":"3055","match_status":"matched","shares":27504,"book_value_yen":25000000,"prior_shares":27504,"prior_book_value_yen":24000000,"purpose_ja":"医薬品事業の販売取引関係の維持・強化を目的に株式を保有しています。定量的な保有効果を示す事が困難なことから記載は省略していますが、「保有目的の合理性」と保有資産としての「経済的合理性」を検証し、2026年4月の取締役会において検証結果を確認、保有の可否を判断しています。","reciprocal":"無","pct_outstanding":0.13379904846226442,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.008574829103655965,"pct_of_holder_assets":0.0072179443871820854,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":291551000000,"holder_total_assets_yen":346359000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"林兼産業㈱","held_name_en":"Hayashikane  Sangyo  Co.,Ltd.","held_sec_code":"2286","match_status":"matched","shares":8186,"book_value_yen":7000000,"prior_shares":8186,"prior_book_value_yen":4000000,"purpose_ja":"機能食品事業の販売取引関係の維持・強化を目的に株式を保有しています。定量的な保有効果を示す事が困難なことから記載は省略していますが、「保有目的の合理性」と保有資産としての「経済的合理性」を検証し、2026年4月の取締役会において検証結果を確認、保有の可否を判断しています。","reciprocal":"無","pct_outstanding":0.1002412353207695,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.00240095214902367,"pct_of_holder_assets":0.002021024428410984,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":291551000000,"holder_total_assets_yen":346359000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"久光製薬㈱","held_name_en":"HISAMITSU PHARMACEUTICAL CO.,INC.","held_sec_code":null,"match_status":"matched","shares":null,"book_value_yen":null,"prior_shares":121500,"prior_book_value_yen":491000000,"purpose_ja":"協力関係の構築を目的に株式を保有しています。定量的な保有効果を示す事が困難なことから記載は省略していますが、「保有目的の合理性」と保有資産としての「経済的合理性」を検証した結果、当事業年度（2025年度）に売却しました。","reciprocal":"有","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2025-02-28","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":291551000000,"holder_total_assets_yen":346359000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"㈱松風","held_name_en":"SHOFU INC.","held_sec_code":"7979","match_status":"matched","shares":null,"book_value_yen":null,"prior_shares":540000,"prior_book_value_yen":1139000000,"purpose_ja":"協力関係の構築を目的に株式を保有しています。定量的な保有効果を示す事が困難なことから記載は省略していますが、「保有目的の合理性」と保有資産としての「経済的合理性」を検証した結果、当事業年度（2025年度）に売却しました。","reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":291551000000,"holder_total_assets_yen":346359000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false}],"holders":[{"holder_name":"株式会社京都銀行","holder_name_en":"The Bank of Kyoto，Ltd.","holder_sec_code":"8369","doc_id":"S100R9CL","period_end":"2023-03-31","holder_table":"reporting","shares":3090000,"book_value_yen":18014000000,"prior_shares":3090000,"prior_book_value_yen":25740000000,"purpose_ja":"銀行取引全般における長期安定的な関係強化及び銀行取引以外の様々なサービス・情報の連携などを通じた、取引先及び当行の長期的な企業価値向上並びに、共に京都に本社を置く企業として地域活性化の促進などのため保有。","reciprocal":"有","pct_outstanding":4.587776820366,"pct_unavailable":null,"pct_basis_period_end":"2023-03-31","pct_share_classes":1,"pct_of_holder_equity":1.8152375558885383,"pct_of_holder_assets":0.16320560672051226,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":992377000000,"holder_total_assets_yen":11037611000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"株式会社京都フィナンシャルグループ","holder_name_en":"Kyoto Financial Group, Inc.","holder_sec_code":"5844","doc_id":"S100YEHZ","period_end":"2026-03-31","holder_table":"largest","shares":3090000,"book_value_yen":15799000000,"prior_shares":3090000,"prior_book_value_yen":11748000000,"purpose_ja":"銀行取引全般における長期安定的な関係強化及び銀行取引以外の様々なサービス・情報の連携などを通じた、取引先及び当社グループの長期的な企業価値向上並びに、共に京都に本社を置く企業として地域活性化の促進などのため保有。","reciprocal":"有","pct_outstanding":4.584502801917551,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":1.390449821386296,"pct_of_holder_assets":0.13359924083768304,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":1136251000000,"holder_total_assets_yen":11825666000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"株式会社三菱ＵＦＪフィナンシャル・グループ","holder_name_en":"Mitsubishi UFJ Financial Group, Inc.","holder_sec_code":"8306","doc_id":"S100YJQO","period_end":"2026-03-31","holder_table":"largest","shares":2706850,"book_value_yen":13840000000,"prior_shares":null,"prior_book_value_yen":null,"purpose_ja":"発行会社グループとの、主に金融取引(預金・貸出・為替等)における総合的な取引関係維持・拡大のために保有","reciprocal":"有","pct_outstanding":4.016039291058421,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.058288036565803655,"pct_of_holder_assets":0.003205695776487476,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":23744152000000,"holder_total_assets_yen":431731548000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"東京海上ホールディングス株式会社","holder_name_en":"Tokio Marine Holdings, Inc.","holder_sec_code":"8766","doc_id":"S100YLS8","period_end":"2026-03-31","holder_table":"largest","shares":783500,"book_value_yen":4006000000,"prior_shares":881500,"prior_book_value_yen":3351000000,"purpose_ja":"保険事業における顧客企業との長期的かつ安定的な保険取引関係の維持および強化を図り、当社グループの企業価値を高めることを目的として、保有してきたものです。現在は、当社グループのリスクポートフォリオを見直し、社会課題解決や成長分野等に対して資本を振り向けるため、売却方針に則り保有をゼロにすることをめざしています。","reciprocal":"有","pct_outstanding":1.1624459369910682,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.07340261812443667,"pct_of_holder_assets":0.012533657218554319,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":5457571000000,"holder_total_assets_yen":31961940000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"小野薬品工業株式会社","holder_name_en":"ONO　PHARMACEUTICAL　CO.,　LTD.","holder_sec_code":"4528","doc_id":"S100YOIE","period_end":"2026-03-31","holder_table":"reporting","shares":620000,"book_value_yen":3170000000,"prior_shares":620000,"prior_book_value_yen":2357000000,"purpose_ja":"医薬品事業において、事業上の関係を維持・強化し、中長期的に企業価値の向上を図るために株式を保有しています。定量的な保有効果については記載が困難であります。保有の合理性は、「保有の合理性を検証する方法」（注３）に記載したような観点に着目し、取締役会において、保有の適否を検証しています。","reciprocal":"有","pct_outstanding":0.9198678761129065,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.3726224746599085,"pct_of_holder_assets":0.2864850453902568,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":850727000000,"holder_total_assets_yen":1106515000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"三菱倉庫株式会社","holder_name_en":"Mitsubishi Logistics Corporation","holder_sec_code":"9301","doc_id":"S100YA7K","period_end":"2026-03-31","holder_table":"reporting","shares":494000,"book_value_yen":2525000000,"prior_shares":494000,"prior_book_value_yen":1878000000,"purpose_ja":"同社株式は、主に物流事業(倉庫、陸上運送事業)における営業取引関係の維持・強化を目的とするほか、資本コスト、配当・取引額等に加え、事業上の関係等を総合的に判断し保有しています。定量的な保有効果については取引先との営業機密があるため記載しませんが、定量的及び定性的評価に基づき、保有の合理性があると判断しています。 ","reciprocal":"有","pct_outstanding":0.7329269851609288,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.6566679756681759,"pct_of_holder_assets":0.39466321551268707,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":384517000000,"holder_total_assets_yen":639786000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"株式会社メディパルホールディングス","holder_name_en":"MEDIPAL HOLDINGS CORPORATION","holder_sec_code":"7459","doc_id":"S100YI1C","period_end":"2026-03-31","holder_table":"reporting","shares":269372,"book_value_yen":1377000000,"prior_shares":269372,"prior_book_value_yen":1024000000,"purpose_ja":"・当社グループの医療用医薬品等卸売事業の商品の仕入等における良好な取引関係の維持・強化のため、保有しております。・定量的な保有効果については、（注）１に記載しております。","reciprocal":"有","pct_outstanding":0.39965588632949334,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.17312066019695777,"pct_of_holder_assets":0.07164404615603938,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":795399000000,"holder_total_assets_yen":1922002000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"株式会社堀場製作所","holder_name_en":"HORIBA, Ltd.","holder_sec_code":"6856","doc_id":"S100XSIJ","period_end":"2025-12-31","holder_table":"reporting","shares":221000,"book_value_yen":1248000000,"prior_shares":221000,"prior_book_value_yen":881000000,"purpose_ja":"・保有目的販売先として事業上の良好な信頼関係の維持及び、業務のより円滑な推進を目的に株式を継続的に保有しています。・定量的な保有効果（注）１","reciprocal":"有","pct_outstanding":0.3278883880983103,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.35796236805874254,"pct_of_holder_assets":0.24079694527464937,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":348640000000,"holder_total_assets_yen":518279000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"株式会社　ジーエス・ユアサ　コーポレーション","holder_name_en":"GS Yuasa Corporation","holder_sec_code":"6674","doc_id":"S100YH71","period_end":"2026-03-31","holder_table":"largest","shares":232500,"book_value_yen":1188000000,"prior_shares":232500,"prior_book_value_yen":883000000,"purpose_ja":"(保有目的)当社グループの取引先として事業上の関係の維持により地元企業との円滑な関係を維持するために保有しております。(業務提携等の概要)同社とは定期的に業務に関する情報交換を行っております。(定量的な保有効果)(注)１。","reciprocal":"有","pct_outstanding":0.34495045354234,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.26750852289359556,"pct_of_holder_assets":0.16032713212818073,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":444098000000,"holder_total_assets_yen":740985000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"宝ホールディングス株式会社","holder_name_en":"TAKARA HOLDINGS INC.","holder_sec_code":"2531","doc_id":"S100YINV","period_end":"2026-03-31","holder_table":"reporting","shares":203200,"book_value_yen":1038000000,"prior_shares":254000,"prior_book_value_yen":965000000,"purpose_ja":"関係維持を通じた経営活動の円滑化、企業価値の向上を図るため保有しておりますが、当事業年度中に一部売却を行いました。","reciprocal":"有","pct_outstanding":0.3014792781066816,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.333829682540193,"pct_of_holder_assets":0.20202374070895152,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":310937000000,"holder_total_assets_yen":513801000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"株式会社　島津製作所","holder_name_en":"Shimadzu Corporation","holder_sec_code":"7701","doc_id":"S100YGJF","period_end":"2026-03-31","holder_table":"reporting","shares":181080,"book_value_yen":925000000,"prior_shares":181080,"prior_book_value_yen":688000000,"purpose_ja":"計測機器での取引および協力関係の維持・強化により、中長期的な企業価値向上を図るため保有しています。","reciprocal":"有","pct_outstanding":0.26866076613955664,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.1636687274181391,"pct_of_holder_assets":0.1253424898845223,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":565166000000,"holder_total_assets_yen":737978000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"養命酒製造株式会社","holder_name_en":"YOMEISHU SEIZO CO., LTD.","holder_sec_code":"2540","doc_id":"S100YK3W","period_end":"2026-03-31","holder_table":"reporting","shares":162000,"book_value_yen":828306000,"prior_shares":162000,"prior_book_value_yen":615924000,"purpose_ja":"医薬品分野における取引・協力関係の構築による企業価値向上を図るため株式を保有しております。","reciprocal":"無","pct_outstanding":0.2403525740811143,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":1.7872366593394737,"pct_of_holder_assets":1.532597717661576,"holder_equity_basis":"parent_only","holder_equity_yen":46345625000,"holder_total_assets_yen":54045885000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"株式会社たけびし","holder_name_en":"TAKEBISHI CORPORATION","holder_sec_code":"7510","doc_id":"S100YHGY","period_end":"2026-03-31","holder_table":"reporting","shares":156000,"book_value_yen":797000000,"prior_shares":156000,"prior_book_value_yen":593000000,"purpose_ja":"同社は当社の主要取引先であります。保有目的は取引関係の維持及び強化です。定量的な保有効果の記載については守秘義務等の観点から困難でありますが、保有の合理性については事業戦略上の重要性や事業上の関係等を踏まえて十分に検証を実施しております","reciprocal":"有","pct_outstanding":0.2314506268929249,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":1.8015370705244123,"pct_of_holder_assets":1.2282513214874633,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":44240000000,"holder_total_assets_yen":64889000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"久光製薬株式会社","holder_name_en":"HISAMITSU PHARMACEUTICAL CO.,INC.","holder_sec_code":"4530","doc_id":"S100VT69","period_end":"2025-02-28","holder_table":"reporting","shares":165000,"book_value_yen":649000000,"prior_shares":165000,"prior_book_value_yen":787000000,"purpose_ja":"協力関係の構築により、企業価値向上を図るため。","reciprocal":"有","pct_outstanding":0.24488456913168563,"pct_unavailable":null,"pct_basis_period_end":"2025-03-31","pct_share_classes":1,"pct_of_holder_equity":0.23227764515563318,"pct_of_holder_assets":0.18917532384250352,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":279407000000,"holder_total_assets_yen":343068000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"科研製薬株式会社","holder_name_en":"KAKEN PHARMACEUTICAL CO., LTD.","holder_sec_code":"4521","doc_id":"S100YK2Q","period_end":"2026-03-31","holder_table":"reporting","shares":125700,"book_value_yen":642000000,"prior_shares":125700,"prior_book_value_yen":477000000,"purpose_ja":"原材料仕入に係る取引円滑化のため、当社の持続成長や企業価値向上から総合的に判断し保有しております。","reciprocal":"有","pct_outstanding":0.18649579359256832,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.43490336609786,"pct_of_holder_assets":0.3602349944169187,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":147619000000,"holder_total_assets_yen":178217000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"キッセイ薬品工業株式会社","holder_name_en":"KISSEI PHARMACEUTICAL CO., LTD.","holder_sec_code":"4547","doc_id":"S100YFN3","period_end":"2026-03-31","holder_table":"reporting","shares":122000,"book_value_yen":623000000,"prior_shares":122000,"prior_book_value_yen":463000000,"purpose_ja":"同社は医薬品事業における取引先の一つであるため、取引関係維持・強化のために株式を保有しています。具体的には、代謝内分泌用薬剤の製造委託先です。2026年４月の取締役会において、個別の政策保有株式について、保有目的、保有に伴う便益・リスク、資本コスト等を総合的に検証し、経済合理性・戦略妥当性を確認しています。","reciprocal":"有","pct_outstanding":0.18100625949318486,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.26907262801465,"pct_of_holder_assets":0.22647462975215024,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":231536000000,"holder_total_assets_yen":275086000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"東邦ホールディングス株式会社","holder_name_en":"TOHO HOLDINGS CO.,LTD.","holder_sec_code":"8129","doc_id":"S100YHSN","period_end":"2026-03-31","holder_table":"reporting","shares":96959,"book_value_yen":495000000,"prior_shares":96959,"prior_book_value_yen":368000000,"purpose_ja":"医薬品の仕入れ等の取引において緊密な関係を維持するため","reciprocal":"有","pct_outstanding":0.1438539829032763,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.18228015908086612,"pct_of_holder_assets":0.06682136825863515,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":271560000000,"holder_total_assets_yen":740781000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"株式会社バイタルケーエスケー・ホールディングス","holder_name_en":"VITAL KSK HOLDINGS,INC.","holder_sec_code":"3151","doc_id":"S100YDSN","period_end":"2026-03-31","holder_table":"largest","shares":79279,"book_value_yen":405000000,"prior_shares":79279,"prior_book_value_yen":301000000,"purpose_ja":"①商品の確保や仕入の円滑化のため　②該当なし　③ＡがＢを上回っております　④該当なし","reciprocal":"有","pct_outstanding":0.11762291185541149,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.3411761732669514,"pct_of_holder_assets":0.12633824960694767,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":118707000000,"holder_total_assets_yen":320568000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"丸大食品株式会社","holder_name_en":"MARUDAI FOOD CO., LTD.","holder_sec_code":"2288","doc_id":"S100YD4W","period_end":"2026-03-31","holder_table":"reporting","shares":47500,"book_value_yen":242000000,"prior_shares":47500,"prior_book_value_yen":180000000,"purpose_ja":"原材料等の仕入取引を行っており、事業上の関係を勘案し、取引関係や協力関係の維持・強化を図るため、継続して保有しています。","reciprocal":"有","pct_outstanding":0.07047374857316623,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.3144041262293591,"pct_of_holder_assets":0.19415762068661194,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":76971000000,"holder_total_assets_yen":124641000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"ＮＩＳＳＨＡ株式会社","holder_name_en":"Nissha Co., Ltd.","holder_sec_code":"7915","doc_id":"S100XS06","period_end":"2025-12-31","holder_table":"reporting","shares":42242,"book_value_yen":238000000,"prior_shares":42242,"prior_book_value_yen":168000000,"purpose_ja":"当社その他事業の製品販売先であり、当社との良好な取引関係を維持・発展させるため","reciprocal":"有","pct_outstanding":0.06267267552058291,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.20638939956294008,"pct_of_holder_assets":0.09515432592355669,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":115316000000,"holder_total_assets_yen":250120000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"朝日印刷株式会社","holder_name_en":"ASAHI PRINTING CO.,LTD.","holder_sec_code":"3951","doc_id":"S100YEXW","period_end":"2026-03-31","holder_table":"reporting","shares":30000,"book_value_yen":153000000,"prior_shares":30000,"prior_book_value_yen":114000000,"purpose_ja":"医薬品パッケージ等の取引先であり、安定的・長期的な取引関係の維持・強化を目的に保有しております。定量的な保有効果については秘密保持の観点から記載しておりませんが、保有意義や取引状況、経済合理性を取締役会において検証し、保有の合理性があると判断しております。","reciprocal":"―","pct_outstanding":0.04450973594094709,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.41649652919559005,"pct_of_holder_assets":0.22117817130466208,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":36735000000,"holder_total_assets_yen":69175000000,"implausible":false,"reciprocal_held_both_ways":null},{"holder_name":"北興化学工業株式会社","holder_name_en":"HOKKO CHEMICAL INDUSTRY CO.,LTD.","holder_sec_code":"4992","doc_id":"S100XVAV","period_end":"2025-11-30","holder_table":"reporting","shares":36000,"book_value_yen":131000000,"prior_shares":36000,"prior_book_value_yen":157000000,"purpose_ja":"ファインケミカル事業における業務（販売）面や強化分野における協力関係を維持するため。","reciprocal":"有","pct_outstanding":0.053411683129136515,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.24763705103969755,"pct_of_holder_assets":0.16881443298969073,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":52900000000,"holder_total_assets_yen":77600000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"株式会社マツキヨココカラ＆カンパニー","holder_name_en":"MatsukiyoCocokara&Co.","holder_sec_code":"3088","doc_id":"S100YD1I","period_end":"2026-03-31","holder_table":"reporting","shares":11094,"book_value_yen":56000000,"prior_shares":11094,"prior_book_value_yen":42000000,"purpose_ja":"（保有目的）商品の安定供給（商品仕入）を通じた当社事業の円滑化のため保有（定量的な保有効果）（注）２ ","reciprocal":"無","pct_outstanding":0.016459700350962236,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.010285590438809002,"pct_of_holder_assets":0.0074090636663486946,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":544451000000,"holder_total_assets_yen":755831000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"松田産業株式会社","holder_name_en":"MATSUDA SANGYO Co.,Ltd.","holder_sec_code":"7456","doc_id":"S100YGWM","period_end":"2026-03-31","holder_table":"reporting","shares":1731,"book_value_yen":8000000,"prior_shares":1731,"prior_book_value_yen":6000000,"purpose_ja":"取引先との関係強化による収益拡大のため保有しており、主に食品関連事業における取引を行っております。","reciprocal":"無","pct_outstanding":0.002568211763792647,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.006719922048904233,"pct_of_holder_assets":0.0035122996342818007,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":119049000000,"holder_total_assets_yen":227771000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"株式会社松風","holder_name_en":"SHOFU INC.","holder_sec_code":"7979","doc_id":"S100YGMA","period_end":"2026-03-31","holder_table":"reporting","shares":null,"book_value_yen":null,"prior_shares":244000,"prior_book_value_yen":927000000,"purpose_ja":"保有の意義や妥当性が希薄であると認められたため、当事業年度において売却しております。","reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":48689000000,"holder_total_assets_yen":57706000000,"implausible":false,"reciprocal_held_both_ways":false}],"reclassified":[],"reclassified_note":"As filed, from the annual report's 保有目的を変更した投資株式 table. direction=to_pure means the filer moved the holding from a policy shareholding to 純投資目的 (pure investment); the shares are not necessarily sold, and the position leaves the named policy table in the year of the change. direction=to_policy is the reverse. fy_of_change_ja is the fiscal year the filer states the change took effect, verbatim — some filers list more than one. A filing repeats these rows for several years after the change, so this is a standing disclosure, not a one-year event.","implausible_note":"A row is flagged implausible when its two filed numbers are mutually impossible — book value ÷ shares of ¥1,000,000 or more, which no listed Japanese share reaches. It is a filer tagging error (a value entered at the wrong scale, or a share count in thousands), not an extraction error: the values match the filing's XBRL exactly. Flagged rows are still returned, exactly as filed, but are excluded from the yen aggregates here and counted in excluded_positions / excluded_yen so the exclusion is visible.","notes":[],"notes_note":"The filing's own numbered footnotes to the named policy table, verbatim. The XBRL numbers them (注)1, (注)2 … and gives no link back to a row, so a note is tied to a position only where it names that issuer.","flows":[{"holder_table":"reporting","share_class":"listed","issues_increased":1,"acquisition_cost_yen":1000000,"issues_decreased":5,"sale_proceeds_yen":4938000000,"entity_scope":"parent_only","share_scope":"listed"},{"holder_table":"reporting","share_class":"unlisted","issues_increased":null,"acquisition_cost_yen":null,"issues_decreased":null,"sale_proceeds_yen":null,"entity_scope":"parent_only","share_scope":"unlisted"}],"flows_note":"The filer's own tally, as filed, of how many issues increased or decreased during the year and the yen involved — acquisition cost for increases, sale proceeds for decreases. Read against the reclassification table this separates what was actually sold from what merely changed category. Counts are as filed and are not corrected for filer tagging errors.","no_reduction_measure":"This product holds sale proceeds (売却価額), as filed, for one fiscal year. It does NOT hold a book-value-reduction measure. The two are different measures and must never be presented as equivalent.","scale":{"policy_total_yen":55547000000,"listed_yen":55220000000,"unlisted_yen":327000000,"listed_issues":24,"unlisted_issues":19,"equity_yen":291551000000,"equity_basis":"ifrs_consolidated_excl_nci","total_assets_yen":346359000000,"assets_basis":"ifrs_consolidated","pct_of_equity":19.052241288831112,"pct_of_assets":16.037406274992133,"equity_basis_label":"Consolidated equity attributable to owners of the parent (IFRS)","assets_basis_label":"Consolidated total equity (IFRS)","equity_calc":"total policy shareholdings ÷ shareholders' equity × 100, both as filed in this annual securities report","assets_calc":"total policy shareholdings ÷ total assets × 100, both as filed in this annual securities report"},"scale_entities":[{"holder_table":"reporting","share_class":"listed","book_value_yen":55220000000,"issue_count":24,"holder_table_label":"The filer itself","entity_scope":"parent_only","share_scope":"listed"},{"holder_table":"reporting","share_class":"unlisted","book_value_yen":327000000,"issue_count":19,"holder_table_label":"The filer itself","entity_scope":"parent_only","share_scope":"unlisted"}],"scale_history":[{"year":"2021","period_end":"2021-03-31","policy_total_yen":20520000000,"equity_yen":162543000000,"equity_basis":"jgaap_consolidated","pct_of_equity":12.624351710009044,"pct_of_assets":10.414763383884525},{"year":"2022","period_end":"2022-03-31","policy_total_yen":19013000000,"equity_yen":176767000000,"equity_basis":"jgaap_consolidated","pct_of_equity":10.755966894273252,"pct_of_assets":9.051568183116562},{"year":"2023","period_end":"2023-03-31","policy_total_yen":19119000000,"equity_yen":195625000000,"equity_basis":"ifrs_consolidated_excl_nci","pct_of_equity":9.77329073482428,"pct_of_assets":8.051766469713751},{"year":"2024","period_end":"2024-03-31","policy_total_yen":29712000000,"equity_yen":220224000000,"equity_basis":"ifrs_consolidated_excl_nci","pct_of_equity":13.491717523975588,"pct_of_assets":11.280010933774735},{"year":"2025","period_end":"2025-03-31","policy_total_yen":34828000000,"equity_yen":247028000000,"equity_basis":"ifrs_consolidated_excl_nci","pct_of_equity":14.098806613015528,"pct_of_assets":12.2790750148958},{"year":"2026","period_end":"2026-03-31","policy_total_yen":55547000000,"equity_yen":291551000000,"equity_basis":"ifrs_consolidated_excl_nci","pct_of_equity":19.052241288831112,"pct_of_assets":16.037406274992133}],"scale_note":"The policy total is Official (as filed) — the filing's own total carrying amount for the whole policy bucket, listed and unlisted, summed across the entities the filing discloses. It is a floor: holdings at group companies the filing does not name are disclosed nowhere and are not included. The percentages are calculated, not filed, and carry their formula. equity_basis names which figure the denominator is, because filers report under Japanese, IFRS or US accounting standards and an adopter of the latter two stops tagging the Japanese consolidated figure — a parent-only denominator is a different measure and is labelled as one, never silently mixed with a group figure. Percentages are null where equity or total assets is missing or not positive; missing is never shown as zero.","scale_reference":"ISS's Japan proxy voting guidelines recommend a vote against the top executive at a company that allocates 20 percent or more of its net assets to cross-shareholdings, a policy effective from February 2022. ISS counts unilateral holdings, not only mutual ones.","ownership_calc":"shares held ÷ (issuer's issued shares − treasury shares) × 100, both as filed, the denominator taken from the issuer's own annual securities report nearest the holding's fiscal year end","ownership_note":"Derived, not filed. The denominator is the issuer's own reported issued shares less treasury shares, from its annual report nearest this holding's fiscal year end on either side — pct_basis_period_end gives that date, and it can fall after the holding's date where that report is the closer one. For a single-class listed stock this equals the stake's share of market capitalisation. It is null where the issuer files no annual report we hold; where the issuer's share count moves by half or more across the window, because a split or issue makes the share base indeterminate; and where the result would exceed 100%, which is a data fault rather than a stake. It is less exact where the issuer has more than one share class (pct_share_classes > 1), because treasury shares are reported across all classes.","holder_share_calc":"this position's book value ÷ the holder's shareholders' equity (or total assets) × 100, both as filed in the holder's own annual securities report","holder_share_note":"The mirror of pct_outstanding. That sizes a stake against the ISSUER — how much of the issuer this holder owns. pct_of_holder_equity and pct_of_holder_assets size the same position against the HOLDER: how much of its own capital is committed to this one name. Calculated, not filed. Null where the holder's filing gives no usable denominator, never zero. holder_equity_basis says which accounting figure the denominator is, and a parent_only basis is not comparable with a consolidated one. A position CAN legitimately exceed 100% of equity — a holder whose book equity is smaller than one long-held stake is a real and commercially interesting case, not an error — so no ceiling is imposed. Extreme values are worth checking against the filing: where the position's own two filed numbers are mutually impossible the row is marked `implausible`, but that test catches only scale errors visible per share, so it does not catch every bad figure. The book value and share count are returned alongside so the reader can check.","action_calc":"keyword match over the filing's own stated purpose and table footnotes: 株式分割、株式併合、株式交換、株式移転、会社分割、合併、持株会社、商号変更、公開買付、上場廃止","ratio_calc":"current shares ÷ prior shares where that ratio is an exact whole number (or its exact reciprocal) — the signature of a split or a consolidation rather than a trade","history":[{"year":"2021","period_end":"2021-03-31","named_holdings":33,"book_value_yen":20180000000},{"year":"2022","period_end":"2022-03-31","named_holdings":29,"book_value_yen":18675000000},{"year":"2023","period_end":"2023-03-31","named_holdings":28,"book_value_yen":18780000000},{"year":"2024","period_end":"2024-03-31","named_holdings":27,"book_value_yen":29371000000},{"year":"2025","period_end":"2025-03-31","named_holdings":27,"book_value_yen":34486000000},{"year":"2026","period_end":"2026-03-31","named_holdings":26,"book_value_yen":55208000000}],"history_note":"One point per annual report filed. Each year's book value is as filed; book values are fair-valued at period end, so a change reflects both trading and market moves.","provenance":{"trust":"official","note":"Figures exactly as filed in each company's 有価証券報告書 (annual securities report), EDINET. Raw filings archived with SHA-256; doc_id links to the source filing."}}